iBio Inc. reported preclinical data for its obesity drug candidate, IBIO-610, during the ObesityWeek 2026 conference held on November 15 in National Harbor, Maryland.
The study evaluated the antibody’s impact on weight and fat composition in non-human primates over a 28-week period.
Researchers administered IBIO-610 to five obese non-human primates, while a control group of six animals received a placebo. All subjects remained on a high-fat diet throughout the duration of the study. By the 18th week, the IBIO-610 group showed a divergence in weight compared to the control group, finishing the 28-week trial with a 2.3% lower body weight.
The data indicated specific fat deposits decreased by the 24th week. Animals treated with IBIO-610 showed 9.6% less total body fat, 16.6% less abdominal subcutaneous fat, and 10.96% less visceral fat than the control group.
The company reported that lean body mass remained largely stable throughout the study.
IBIO-610 functions as an antibody targeting Activin E. According to iBio, the treatment effectively suppressed active Activin E levels through the end of the 28-week observation period.
In addition to the IBIO-610 results, iBio released preclinical data regarding its separate amylin program, which utilizes peptide agonists linked to receptor-targeting antibodies. In vitro experiments demonstrated that these antibody-peptide conjugates selectively bind to and activate amylin receptors 1 and 3, with minimal binding affinity for the calcitonin receptor alone.
In a single-dose study involving lean mice, those treated with the selective amylin receptor agonist exhibited lower 24-hour food intake compared to the control group. iBio plans to advance this program into further preclinical testing using diet-induced obesity models.
The company intends to share further details regarding its amylin program at two upcoming industry events. Data will be presented at PEGS Europe 2026 on November 19, followed by the Amylin-Based Therapeutics Summit held from December 1 to December 2.
Worth a look